Navigation Links
Cephalon Wins FENTORA Patent Suit Against Watson

FRAZER, Pa., March 24, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced that today the United States District Court in Delaware upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found that Watson Pharmaceuticals, Inc.'s proposed generic version of FENTORA® (fentanyl buccal tablet) infringes that patent.  The Court also denied Watson's motion to vacate a previously entered injunction preventing Watson from marketing its product.

"We are pleased with the court's ruling upholding the validity of our patent, as well as its finding that Watson's product infringes that patent," said Jerry Pappert, Executive Vice President and General Counsel of Cephalon.  

This decision pertained to patent litigation brought by Cephalon and its wholly-owned subsidiary CIMA Labs, Inc., against Watson Pharmaceuticals, Inc., and its wholly-owned subsidiary Watson Laboratories, Inc., regarding Cephalon's FENTORA product.  

FENTORA was approved by the U.S. Food and Drug Administration (FDA) in September 2006.

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at

Cephalon Forward-Looking Statement

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.



Natalie de Vane
O: 610-727-6536
C: 610-999-8756

Fritz Bittenbender
O: 610-883-5885
C: 610-457-7041


Robert (Chip) Merritt
O: 610-738-6376

Joseph Marczely
O: 610-883-5894

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Definitive Agreement to Acquire Gemin X
2. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
3. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
4. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
5. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
6. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
7. Cephalon to Webcast Investor Day
8. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
9. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
10. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
11. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... 24, 2015  Boston Scientific Corporation (NYSE: BSX ... Annual Healthcare Conference on December 8, in ... , vice president, Investor Relations, will participate in a ... approximately 8:35 a.m. ET. --> Susie Lisa ... 30-minute question-and-answer session with the host analyst beginning at ...
(Date:11/24/2015)... Pharmaceuticals, Inc. (NASDAQ: IMMY ) is a ... of novel compounded pharmaceuticals.  The company,s business primarily ... sinus and integrative medicine.  Imprimis dispenses compounded pharmaceuticals ... in California , ... and Pennsylvania.  For more information about Imprimis, ...
Breaking Medicine Technology:
(Date:11/24/2015)... Geneva, IL (PRWEB) , ... November 24, 2015 , ... All her life, Don Peck’s ... Even her obituary said she might have been. After a 25-year search for ... Mayflower voyager with whom she shared a last name. Turns out, it was Don’s ...
(Date:11/24/2015)... ... 2015 , ... Dehydration, defined as a loss of body water content, can ... sun, and heat stroke and death will quickly follow. A normal human body is ... cell, system and structure requires water to function properly. Kleyne, who believes that medical ...
(Date:11/24/2015)... Dublin, CA (PRWEB) , ... November 24, 2015 ... ... Community College District , the only authorized OSHA Training Institute Education Center in ... workplace injuries during the holiday season’s major sales events. As the volume ...
(Date:11/24/2015)... ... November 24, 2015 , ... Add a fresh touch to this ... and affordable way to bring long-lasting style and cheer to any space. , Holiday ... the air and keep on giving all year long. , “Holiday plants make a ...
(Date:11/24/2015)... ... November 24, 2015 , ... Take the audience on a journey with TransFrame Cloud ... through a cloud of images without ever setting a single keyframe in Final Cut Pro ... Then use the controls to change the angle and depth of field to create a ...
Breaking Medicine News(10 mins):